ASH 2011

Lenalidomide + Azacitidine Well Tolerated, Highly Active in Patients with Higher-Risk Myelodysplastic Syndromes

A multicenter, Phase 2 continuation trial has shown that the positive overall response rate (ORR) seen in a Phase 1 trial evaluating lenalidomide + azacitidine combination therapy is substantiated, with good overall survival (OS), even among progressing patients, in a higher-risk myelodysplastic syndromes (MDS) population. The study was presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

RESORT Study: Rituximab Retreatment Produces Outcomes Comparable to Maintenance Rituximab Treatment in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma

A study of two different strategies for managing patients with asymptomatic low-tumor-burden (LTB) follicular lymphoma (FL) found retreatment with rituximab at disease progression is as effective in managing the disease as ongoing maintenance therapy, results of RESORT, a Phase 3 Eastern Cooperative Oncology Group (ECOG) study, reported at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Lenalidomide-Based Therapies Prolong Time to Progression to Symptomatic Disease in High-Risk Smoldering Multiple Myeloma

Lenalidomide-dexamethasone (Len-dex) induction therapy, followed by lenalidomide maintenance therapy, significantly prolonged time to progression (TTP), as compared to no treatment (standard of care), as per results of a Phase 3 randomized, multicenter trial of smoldering multiple myeloma (SMM) patients at high-risk of progression to symptomatic disease. The data was presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Some Pain Relief in Sickle Cell Disease Patients with Once-Daily Prasugrel

In a small Phase 2 study presented at the 53rd American Society of Hematology's Annual Meeting and Exposition, once-daily prasugrel 5mg for 30 days showed some promise of decreasing pain in patients with sickle-cell disease (SCD).

ASH 2011

Relapsed and Bortezomib-Refractory Multiple Myeloma (MM) Patients Show Response to Treatment with Panobinostat + Bortezomib + Dexamethasone

Use of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone is promising for patients with bortezomib-refractory MM, results PANORAMA 2, a single arm, Phase 2 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition have found.

ASH 2011

BELA Trial: Bosutinib May Be Superior to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

At the 53rd American Society of Hematology Annual Meeting and Exposition, Jorge E. Cortes, MD of the MD Anderson Cancer Center, Houston, TX, and colleagues presented 24-month follow-up data from the BELA Trial. The BELA trial evaluated the efficacy of bosutinib, an oral, dual competitive inhibitor of the Src and Abl tyrosine kinases, in newly diagnosed chronic phase chronic myeloid leukemia (CP-CML).

ASH 2011

Siltuximab May Partially Overcome Dexamethasone-Resistance in Relapsed or Refractory Multiple Myeloma

Siltuximab in combination with dexamethasone may partially overcome dexamethasone resistance in some cases of multiple myeloma (MM) refractory to prior dexamethasone-containing therapy, reported Peter M. Voorhees, MD, from the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, and colleagues at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

VISTA Follow-Up Supports Survival Benefit in Untreated Multiple Myeloma with Bortezomib-Melphalan-Prednisone

Final results of the international, multicenter, Phase 3 VISTA trial confirmed that after 5 years of follow-up, bortezomib-melphalan-prednisone (VMP) demonstrated a persistent, significant overall survival (OS) benefit versus melphalan-prednisone (MP)—a 13.3 median month increase—in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy investigators reported at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Bortezomib-Based Regimens Similarly Efficacious in Elderly, Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Patients

The community-based, Phase 3b randomized, open-label, multicenter UPFRONT trial presented at the 53rd American Society of Hematology Annual Meeting and Exposition has found that three bortezomib-based regimens followed by weekly bortezomib maintenance therapy produced similar overall response rates (ORR), progression-free survival (PFS), and 1-year overall survival (OS) in elderly, newly diagnosed, transplant-ineligible multiple myeloma (MM) patients.

ASH 2011

Positive Safety Profile of Bendamustine for Pediatric Patients with Relapsed or Refractory AML

The alkylating agent bendamustine has some activity in heavily pretreated pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) but not in those with relapsed or refractory acute myeloid leukemia (AML), according to preliminary data presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.

ASH 2011

Benefit of Romiplostim vs. Standard of Care (SOC) and SOC+Rituximab in Patients with Immune Thrombocytopenia

Jeffrey Wasser, MD, from the Department of Medicine, Division of Hematology-Oncology, University of Connecticut School of Medicine, Farmington, and colleagues report at the 53rd American Society of Hematology Annual Meeting and Exposition that romiplostim may have greater effects on platelet responses than standard of care (SOC) + rituximab or SOC alone in immune thrombocytopenia (ITP).

ASH 2011

Effective Response Rates of Lenalidomide and Rituximab as Initial Treatment of Chronic Lymphocytic Leukemia

Investigators at the 53rd American Society of Hematology Annual Meeting and Exposition presented study data demonstrating high response rates of lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia (CLL).

ASH 2011

Alemtuzumab Plus Fludarabine and Cyclophosphamide More Effective in High-Risk Chronic Lymphocytic Leukemia

Low-dose alemtuzumab in combination with fludarabine and cyclophosphamide (FCA) induced a higher rate and higher quality of complete remission (CR) than fludarabine and cyclophosphamide (FC) alone in a high-risk chronic lymphocytic leukemia (CLL) population, analysis of the HOVON68 trial presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology concluded.

ASH 2011

Overall Survival Not Improved by Lintuzumab + Low-Dose Cytarabine in Older Patients with Untreated AML

Combination therapy of lintuzumab and low-dose cytarabine did not improve overall survival (OS) in older patients with untreated acute myeloid leukemia (AML) when compared with placebo and low-dose cytarabine, according to study results presented at the American Society of Hematology's 53rd Annual Meeting and Exposition.

ASH 2011

Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival

Minimal maternal complications and fetal detriment were observed in pregnant patients with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) who received standard chemotherapy (without anti-metabolites) during their 2nd and 3rd trimesters, according to data from one of the largest studies conducted in this patient group. These results were presented at the American Society of Hematology's 53rd Annual Meeting and Exposition.

ASH 2011

Ruxolitinib in Myelofibrosis Shows Improvement in Spleen Volume, Symptoms, and Overall Survival

Ruxolitinib demonstrated a significant reduction in spleen volume (SV) and improvements in myelofibrosis (MF)-related symptoms in the COMFORT-I study, reported upon at the American Society of Hematology 53rd Annual Meeting and Exposition.

ASH 2011

Low or Intermediate-1 Risk MDS Patients with Thrombocytopenia May Benefit from Romiplostim Therapy

In patients with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS) and thrombocytopenia, use of the thrombopoietin (TPO)-receptor agonist, romiplostim, resulted in a 15-fold increase in platelet response as defined by the International Working Group's (IWG) 2006 criteria for hematologic improvement-platelets (HI-P). The data from this randomized, double-blind, placebo-controlled study was presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Alisertib Generally Well-Tolerated in Patients with B-Cell and T-Cell Non-Hodgkin's Lymphoma

Alisertib, an ATP-competitive, orally available inhibitor of aurora A kinase (AAK), was well-tolerated, with responses observed in heavily pretreated patients with aggressive non-Hodgkin's lymphoma (NHL), including after autologous stem cell transplantation (ASCT), noted study investigators at the 53rd Annual Meeting and Exposition of American Society and Hematology.

ASH 2011

Fractionated 90Y-Ibritumomab Tiuxetan Effective as First-Line Therapy for Relapsed Follicular Lymphoma

Clinical findings presented at the American Society of Hematology's 53rd Annual Meeting and Exposition demonstrated fractionated radioimmunotherapy (RIT) using 90Y-ibritumomab tiuxetan to be effective as initial chemotherapy of advanced-stage follicular lymphoma (FL) in patients with high tumor burden. Dr. Timothy M. Illidge, MD, PhD, of the School of Cancer and Enabling Sciences, University of Manchester, Manchester, UK and colleagues conducted an international, multicenter Phase 2 trial to evaluate the efficacy and toxicity of fractionated 90Y-ibritumomab tiuxetan RIT as a first-line treatment of relapsed FL.

ASH 2011

Excellent PFS and OS Observed with CHOP Combination Regimens in Newly Diagnosed Advanced Stage Follicular Non-Hodgkin's Lymphoma

"In patients with previously untreated, advanced follicular lymphomas (FL)," Joseph Oliver W. Press, MD, PhD, of Fred Hutchinson Cancer Research Center, Seattle, WA, states, "CHOP chemotherapy plus rituximab or CHOP chemotherapy plus 131iodine-tositumomab have produced outstanding progression-free survival (PFS) and overall survival (OS) rates." Dr. Press presented the findings from SWOG-0016, a Phase 3, randomized, intergroup trial at the 53rd American Society of Hematology Meeting and Exposition.

ASH 2011

HyperCVAD Plus Dasatinib Effective in Patients with Ph+ ALL or CML-LB

Combining the hyperCVAD regimen with dasatinib, a dual Scr and BCR-ABL kinase inhibitor, is effective in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia in the lymphoid blast phase (CML-LB), according to investigators at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Rituximab and Liposomal Doxorubicin Improve Progression-Free and Overall Survival When Added to Chemotherapy in Untreated Burkitt's Lymphoma

At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented evidence demonstrating promising survival rates in Burkitt's lymphoma (BL) when rituximab was added to the CODOX-M and IVAC chemotherapy regimens and when liposomal doxorubicin was used in place of doxorubicin in the CODOX-M regimen.

ASH 2011

CLAG in Combination with Imatinib Mesylate Shows Promise in Relapsed or Refractory Acute Myeloid Leukemia

Rami S. Komrokji, MD, from H. Lee Moffitt Cancer Center & Research Institute in Tampa, FL, and colleagues reported study data indicating that the CLAG regimen (cladribine, cytarabine, granulocyte colony stimulating factor) in combination with imatinib mesylate showed encouraging signs of activity in relapsed or refractory (RR) acute myeloid leukemia (AML). Results of this single-institution, two-stage, Phase 2 study were presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

R-BAC Effective In Patients With Mantle Cell Lymphoma Not Eligible for Intensive Chemotherapy or Autologous Transplant

The rituximab, bendamustine and cytarabine (R-BAC) chemotherapy regimen was shown to be effective in previously untreated patients >65 years old with mantle cell lymphoma (MCL), as well as in patients who are relapsed or refractory (R/R) to one previous line of immunochemotherapy, based on results of a prospective Phase 2 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Therapeutic Potential of Bafetinib Observed in Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented data showing that bafetinib has therapeutic potential in the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) who relapsed or were refractory to >1 course of treatment with either an alkylating agent, rituximab, or a fludarabine-based regimen.

ASH 2011

Idarubicin or Mitoxantrone Equally Effective in Pediatric Acute Myeloid Leukemia or Myelodysplasia

In children with newly diagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS), no significant differences in efficacy or toxicity were observed between idarubicin and mitoxantrone induction and first intensification courses, results of a randomized, Phase 3 study presented at the 53rd American Society of Hematology Annual Meeting and Exposition has found.

ASH 2011

Resminostat Has Potential to Offer Substantial Clinical Benefit to Patients with Relapsed or Refractory Hodgkin's Lymphoma

At the 53rd American Society of Hematology Annual Meeting and Exposition, study investigators presented data from the SAPHIRE trial demonstrating that resminostat, an oral pan-histone deacetylase (HDAC) inhibitor, showed considerable anti-tumor activity in a heavily pre-treated population with Hodgkin's Lymphoma.

ASH 2011

Romiplostim Enhances Long-Term Platelet Responses in Thrombocytopenic Patients with Myelodysplastic Syndromes

Long-term use of romiplostim in myelodysplastic syndrome (MDS) patients for up to 3.5 years (five years including therapy on prior studies) produced platelet responses in 83% of patients, according to an open-label extension study presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Rituximab Plus Pulse Dexamethasone Effective, Tolerable in Patients with Immune Thrombocytopenia

Standard-dose rituximab plus multiple courses of pulse dexamethasone was shown to be active with manageable toxicity in patients with immune thrombocytopenia (ITP), according to results of a retrospective analysis presented during the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Patients with Relapsed/Refractory Hodgkin's Lymphoma Benefit from VTEPA Salvage Regimen

A retrospective review reported on during the 53rd American Society of Hematology Annual Meeting and Exposition found vinorelbine, paclitaxel, etoposide, cisplatin and cytarabine (VTEPA) to be a promising salvage regimen in patients with relapsed/refractory Hodgkin's lymphoma. However, patients with refractory diffuse large B-cell lymphoma (DLBCL) had "exceedingly poor" outcomes in comparison.

ASH 2011

Addition of Bortezomib to Thalidomide-Dexamethasone as Post-ASCT Consolidation Therapy Significantly Increases Response and PFS in Multiple Myeloma

Patients with multiple myeloma (MM) had significantly increased rates of complete response (CR) and progression-free survival (PFS)—including superior PFS across poor prognosis subgroups—when postautologous stem cell transplantation (ASCT) consolidation therapy utilized bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone, investigators reported during the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Adding Gemcitabine to First-Line Treatment Regimen Increases Efficacy in Patients with DLBCL

A first-line regimen that incorporated gemcitabine with rituximab, cyclophosphamide, vincristine, and prednisolone (R-GCVP) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-containing chemotherapy delivered "excellent overall response rates" in this challenging population, a Phase 2 study presented during the 53rd American Society of Hematology Annual Meeting and Exposition has found.

ASH 2011

Second-Line Bortezomib + Dexamethasone Active in Patients with Multiple Myeloma

The first prospective study to assess bortezomib + dexamethasone as second-line treatment in patients with multiple myeloma (MM) found the regimen to be feasible and active, investigators concluded during the 53rd American Society of Hematology Annual Meeting and Exposition. In addition, overall renal function was shown to improve with treatment.

ASH 2011

Pixantrone Instead of Doxorubicin in CHOP-R Regimen Has Comparable Efficacy, Reduced Cardiotoxicity in DLBCL

For patients with untreated diffuse large B-cell lymphoma (DLBCL), CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisolone + rituximab) is standard therapy. In a study in which pixantrone dimaleate replaced doxorubicin (CPOP-R), comparable efficacy with reduced cardiotoxicity was observed, investigators reported during the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Erlotinib Shows Promise in Patients with Myelodysplastic Syndrome Following Azanucleoside Treatment Failure

Erlotinib was found to have an acceptable toxicity profile in patients with myelodysplastic syndromes (MDS) and antileukemic activity in those with poor risk MDS in whom treatment with azanucleoside agents has failed, according to results of a Phase 2 study presented during the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Tyrosine Kinase Inhibitors Plus Intensive Chemotherapy Prolong Survival in Patients with Ph+ ALL

Prolonged use of tyrosine kinase inhibitors (TKIs) plus chemotherapy and stem cell transplantation (SCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a disease of predominantly older persons, can achieve long-term survival, according to results of a study reported during the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Fludarabine, Mitoxantrone Plus 90Y-Ibritumomab Tiuxetan Safe, Effective in Treatment-Naive Patients with Follicular Lymphoma

Investigators at the 53rd American Society of Hematology Annual Meeting and Exposition reported that long-term efficacy and toxicity of fludarabine and mitoxantrone followed by radioimmunotherapy with 90Y ibritumomab tiuxetan had six-year rates of progression-free survival (PFS) and overall survival (OS) that compared favorably with chemoimmunotherapy alone in patients with untreated follicular lymphoma (FL).

ASH 2011

Pretreatment with Clofarabine-Containing Regimens Does Not Adversely Affect Outcomes in Younger Patients with AML Undergoing Allo-SCT

Pre-transplant chemotherapy regimens that included the purine nucleoside analog clofarabine did not negatively affect outcomes in younger patients with acute myeloid leukemia (AML) who were undergoing allogenic stem cell transplant (allo-SCT) compared with those pretreated with non-clofarabine containing regimens, according to results of a study reported during the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Oral Lenalidomide May Have Utility as Maintenance Therapy in Patients with Relapsed/Advanced Cutaneous T-Cell Lymphoma

Oral lenalidomide demonstrated activity in patients with relapsed/advanced cutaneous T-cell lymphoma (CTCL) consistent with that of other currently available agents, according to results of a Phase 2 multicenter trial presented at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Risedronate Reduces Some Bone Loss in Patients with ALL/LL Receiving High-Dose Corticosteroids

Adult patients with acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LL) treated with the Hyper-CVAD regimen are at very high risk for rapid bone loss from the high-dose corticosteroid early in their treatment, the first study to show such a loss concluded during at the 53rd American Society of Hematology Annual Meeting and Exposition.

ASH 2011

Eculizumab Shows Efficacy and Tolerability in Pediatric Patients with PNH

An open-label study of seven pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH) found short-term infusions of eculizumab to be well tolerated, with reduced intravascular hemolysis. These results, reported during the 53rd American Society of Hematology Annual Meeting and Exposition, were consistent with those found in adults with this disease and suggest the potential for this treatment in children and adolescents with PNH.

Sign Up for Free e-newsletters